在接受一线化疗免疫治疗的ES-SCLC患者中,irrAEs和生存结果之间的相关性
Federico Monaca1, Igor Gomez-Randulfe2, Ana Sofia Parreira2
1Università Cattolica del Sacro Cuore, Rome, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
European journal of cancer (Oxford, England : 1990)
|April 18, 2025
概括
在接受广泛阶段小细胞肺癌 (ES-SCLC) 化疗免疫疗法 (CT-IO) 的患者中,与免疫相关的不良事件 (irAEs) 与更好的生存结果有关. 这项研究证实,IREs与ES-SCLC患者的无进展和整体存活率的改善有关.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床研究 临床研究
背景情况:
- 化疗免疫疗法 (CT-IO) 改善了扩散阶段小细胞肺癌 (ES-SCLC) 的结果.
- 在ES-SCLC中免疫相关不良事件 (irAEs) 的预后意义仍然不清楚.
- irAEs通常与其他癌症类型的更好的结果有关.
研究的目的:
- 调查与第一线CT-IO治疗的ES-SCLC患者的irAEs和临床结果之间的关联.
- 为了确定该患者群体中irAEs的预后值.
主要方法:
- 在五个欧洲中心对399名ES-SCLC患者进行了第一线CT-IO治疗的回顾性分析.
- 收集的数据包括人口统计和临床特征.
- 使用时间依赖的考克斯回归来评估irrAEs对无进展生存 (PFS) 和整体生存 (OS) 的影响.
主要成果:
- 随访时间中位数为15.0个月,总体应答率为80.3%.
- 与没有irrAEs的患者相比,经历irrAEs的患者 (30.6%) 的中位数PFS (10.8个月与5.3个月) 和mOS (18.8个月与7.6个月) 显著较长.
- 多变量分析证实,irrAEs与改善的生存状况 (HR 0.64) 以及更长的PFS趋势有关.
结论:
- 这项最大规模的研究表明,irAEs与接受一线CT-IO的ES-SCLC患者的改善临床结果有关.
- 在这种情况下,irrAEs的存在可以作为一个积极的预后指标.
相关概念视频
01:21Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
01:20Comparing the Survival Analysis of Two or More Groups
85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85
01:20Actuarial Approach
39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39